Throughout evolution antimicrobial peptides (AMPs 5 ) are found to be an important defensive weapon in virtually all multicellular organisms (1) . AMPs have been recognised as an important part of the innate immune system and have remained effective against bacterial, fungal and viral infections to this day (2) . Today antimicrobial peptides are of great interest in medicine as these peptides have bactericidal effects and are active against a broad range of pathogens.
The sustained effectiveness throughout evolution suggests that antimicrobial peptides limit the opportunity for the development of bacterial resistance and that they could be the means to overcome the increasing problem with bacterial resistance to commonly used antibiotics (3, 4) . AMPs show enormous sequence diversity, and also different classes of structures of AMPs are known. A large group of AMPs have an amphipathic structure and are cationic due to a high content of arginine and lysine residues. The positive charge promotes the binding to membranes of microbes which are generally negatively charged (3) . AMPs have been loosely classified into four classes according to their sequence and structure. These are: amphipathic -helices, loops due to a single disulphide bond, extended molecules and -sheet molecules stabilized by two or more disulfide bonds (3) . Two predominant classes of AMPs in vertebrates are cathelicidins and defensins both containing three conserved disulphide bonds. Cathelicidins are characterized by a highly conserved signal-sequence and pro-regions, whereas the C-terminal domain, encoding the mature peptide, displays much diversity in sequence and structure (5) . Defensins are characterized by a -sheet rich fold stabilized by three conserved intramolecular cysteine disulfide bridges (6) . Defensins are divided into -, -and -defensins. -and -defensins differ in peptide length and the pairing of cysteines in disulfide bonds. The -defensin is a circular peptide isolated from rhesus monkeys (7, 8) . Defensin-like peptides from higher plants and insects have a -defensin like structure (2)(9). Several defensins have been isolated and, surprisingly, defensins from closely related species show less homology than defensins from species of different phyla (10) . Many invertebrate (11) and fungal (12) defensins have a cysteine stabilized -helix/-sheet structure similar to the structure of -defensins from vertebrates. Among others, structures have been solved for Phormia defensin (13) , Sarcophaga defensin (14) , drosomycin (15), heliomicin (16), termicin (17) , MGD-1 (18) , lucifensin (19) , and plectasin (20) . They all form an -helix and two anti-parallel -strands (-scaffold), with the -helix stabilized by two disulfide bridges to one strand of the -sheet. Drosomycin and heliomicin are further characterized by an additional N-terminal -strand (-scaffold) identical to the scaffold of some antifungal plant defensins (11) . AMPs make attractive candidates for therapeutic use for several reasons. They kill their target rapidly, compared to conventional antibiotics the development of antimicrobial resistance is unlikely, and they have additional adjuvant effects on the immune system (21) . In this paper we present the structure and mechanism of action of the new defensin eurocin isolated from the fungus Eurotium amstelodami. The gene encoding eurocin was discovered in a cDNA library of the ascomycete Eurotium amstelodami (US2006/0223751). The cDNA clone encoded a putative defensin-like peptide which was named eurocin. The gene encodes 90 amino acids (signal peptide (aa1-20), propeptide (aa21-48) and defensin peptide (aa49-90)). The mature peptide consists of 42 amino acids ( Fig.  1) and has a molecular mass of 4.3 kDa. Eurocin has a high content (>10%) of both glycine (24%) and cysteine (14%) residues. The peptide encloses six cysteine residues, allowing for the formation of three disulphide bonds. This indicates that eurocin belongs to the group of antimicrobial peptides with β-sheets stabilized by two or more disulphide bonds. Bacterial cell wall biosynthesis represents a most relevant target pathway for antibiotic intervention. Numerous antibiotic classes like glycopeptides, e.g. vancomycin (22) and the lantibiotics (23, 24) have been shown to act via the disruption of this essential biosynthesis pathway through interaction with the cell wall precursor lipid II. Recently, it was shown that eurocin, along with other fungal and metazoan defensins, specifically forms a complex with the central cell wall precursor lipid II (25) . It was also demonstrated that human beta-defensin 3 (26) and human neutrophil peptide-1 (27) bind lipid II. It was therefore obvious to further investigate the structure and the mode of action of eurocin. In the following, we describe the structural characterisation of eurocin by solution-state NMR spectroscopy, its antimicrobial effect in vivo and in vitro and the investigation of its mode of action by a broad range of experiments.
EXPERIMENTAL PROCEDURES
Materials -DHPC and DOPC was from Avanti Phospholipids (Alabaster, AL). Deuteriumlabelled DPC was purchased from Cambridge Isotope Laboratories. All other chemicals used were purchased from Sigma Aldrich.
Peptide production -The gene encoding eurocin was cloned in the A. oryzae proprietary production host as previously described (20) . By a three step purification procedure, we were able to recover grams of purified peptide. More specifically, cells were removed from the fermentation broth by centrifugation at 6000 rpm. The supernatant was filtered (Fast PES bottle top filters, 0.22 μm; Nalgene 595-4520) and adjusted to pH 7.0 with NaOH. The peptide was then captured on a single step MEP HyperCel capture column connected to an ÄKTA explorer 100. The column was equilibrated with 50 mM Phosphate buffer pH 7.0 and peptides eluted with 50 mM formic acid pH 4.0. The fractions containing the peptide was pooled, pH adjusted to 5.0 with NaOH and loaded onto a Ion exchange column equilibrated and washed with 50 mM malonic acid, pH 5.0. The peptide was eluted with a gradient of 50 mM malonic acid, 2 M NaCl, pH 5.0, 0-100% for 50 minutes. Finally, the sample was adjusted to pH 7.0 and loaded onto a 100 ml MEP HyperCel column equilibrated with 50 mM phosphate pH 7.0. The column was washed with phosphate buffer and eluted with 50 mM acetate pH 4.0. At this point, the purity exceeded 95%. 
Bacterial strains and growth conditions -
Chemical shift changes of eurocin were used to calculate the concentration of free and DPCbound eurocin, respectively. A Langmuir isotherm (Eq. 3) was then used to model the binding of eurocin to the DPC micelle (41) . 
number of DPC molecules interacting per molecule eurocin, K is the affinity constant of eurocin for DPC, and G 0 is the Gibb's Free Energy of the interaction. Fluorescence measurements were conducted on an Eclipse fluorimeter (Cary-Varian, Palo Alto, CA). Fluorescence emission was scanned from 310nm to 400nm with an excitation wavelength of 295nm to monitor tryptophan fluorescence of eurocin at pH 6 in the absence and presence of 50 mM DPC.
Intracellular accumulation of the final soluble cell wall precursor UDP-N-acetyl-muramyl
pentapeptide -Analysis of the cytoplasmic peptidoglycan nucleotide precursor pool was examined using the method of Kohlrausch and Höltje (42) with slight modifications. S. simulans 22 was grown in Mueller-Hinton broth to an OD 600 of 0.5 and supplemented with 130 pg/ml of chloramphenicol. After 15 min of incubation, vancomycin and eurocin were added at 10 × MIC (5 µg/ml and 3 µg/ml, respectively) and incubated for another 30 min. Subsequently, cells were rapidly cooled on ice and spun down (15 000 x g, 5 min, 4 °C), resuspended in cold water and, under stirring, extracted with boiling water. Cell debris was removed (48000 × g, 30 min) and the supernatant lyophilized. UDPlinked cell wall precursors were analyzed by reversed-phase HPLC and the identities confirmed by mass spectrometry.
Potassium release from whole cells -Cells of S. carnosus TM300 were harvested at an OD 600 of 1.0-1.5, washed with cold choline buffer (300 mM choline chloride, 30 mM MES, 20 mM Tris, pH 6.5) and resuspended to an OD 600 of 30. The concentrated cell suspension was kept on ice and used within 30 min. For each measurement the cells were diluted in choline buffer, supplemented with 10 mM glucose (25°C) to an OD 600 of about 3. Peptide-induced leakage was monitored relative to the total amount of potassium release after addition of 1 μM of the lantibiotic nisin (positive control) over 300 sec using a potassium-sensitive electrode. Eurocin was added at 1, 3, and 10 × MIC (corresponding to 0.069, 0.21, and 0.69 µM, respectively). The fungal defensin plectasin (10 × MIC (2M)) was used as negative control.
In vitro peptidoglycan synthesis with isolated membranes -In vitro lipid II synthesis was performed using membranes of Micrococcus luteus as previously described (43) . Briefly, synthesis was performed in a total volume of 50 µl containing 150-200 µg of membrane protein, 5 nmol of undecaprenylphosphate (C 55 -P), 50 nmol of UDP-MurNAc-pentapeptide, 50 nmol of UDP-GlcNAc in 60 mM Tris-HCl, 5 mM MgCl 2 , pH 7.5, and 0.6% (w/v) Triton X-100. For quantitative analysis, 14 C-UDP-GlcNAc (0.25 nmol) was added to the reaction mixture. After incubation of 1h at 30°C lipid II synthezised was extracted from the reaction mixture and separated by TLC. Bactoprenol-containing products were extracted with butanol/ pyridine acetate (2:1; vol/vol; pH 4.2) and analyzed by thin layer chromatography (TLC; silica plates, 60F254, Merck). Radiolabeled spots were visualized by iodine vapor, excised and counted. Eurocin was added to the reaction mixture in molar ratios as indicated referring to the total amount of C 55 -P. For purification of milligram quantities of lipid II, the analytical procedure was scaled up by a factor of 500 and purified as described (43) . Radiolabeled lipid II was synthesized using In vitro PBP2 catalyzed transglycosylation using purified enzyme and substrates -Cloning, expression and purification of recombinant PBP2-His 6 was performed as described (25) . Enzymatic activity of PBP2 was determined by incubating 2.5 nmol [ 14 C]-lipid II in 100 mM MES, 10 mM MgCl 2 , pH 5.5, and 0.1% Triton X-100 in a total volume of 50 µl. The reaction was initiated by the addition of 7.5 µg PBP2-His 6 and incubated for 1.5-2 h at 30 °C. Eurocin was added in molar ratios with respect to the lipid II substrate. Analysis of lipid II polymerisation catalyzed by PBP2 was carried out by applying reaction mixtures directly onto TLC plates developed in solvent B (butanolacetic acid-water-pyridine; 15:3:12:10, vol/vol/vol/vol), and subsequent quantification of residual radiolabelled free lipid II using phoshpoimaging.
Complex formation of eurocin with lipid II as analyzed by TLC -Purified [
14 C]-lipid II (2.5 nmol) was incubated in 10 mM Tris/HCl, pH 7.5 in the presence of increasing eurocin concentrations (eurocin:lipid II molar ratios ranging from 0.25 -1:1) in a total volume of 30 µl. After incubation for 30 min at 30 °C, the mixture was analysed by TLC using solvent B (butanol-acetic acid-water-pyridine; 15:3:12:10, vol/vol/vol/vol). Analysis was carried out by phosphoimaging (STORM phospho imager).
Preparation of liposomes -SUVs containing calcein were prepared using stock solutions of DOPC which were first dissolved in methanol and dried in a desiccator for five hours. Lipids were then resuspended by vortexing in an aqueous buffer-free solution of 70 mM calcein (sodium salt) to a final concentration of 10 g/l (~14 mM). The suspension was exposed to at least seven cycles of freezing in liquid nitrogen, followed by thawing in a 50 °C water bath, before extrusion through a 200 nm pore filter 12 times using a 10 ml thermo barrel extruder (Northern Lipids, Vancouver, Canada). The lipid solutions were run on a PD10 column preequilibrated with a 50 mM NaCl solution. Eluent fractions were gathered and tested by fluorescence measurements with and without the addition of Triton X-100 to test for calcein release. Those with the highest signal-tobackground ratio were selected for further use. All extruded vesicles were used the same day that they were made.
Calcein release assay measured by fluorescence -All measurements were conducted on an Eclipse fluorimeter (Cary-Varian, Palo Alto, CA). To monitor the release of free calcein from the vesicles and the concomitant rise in fluorescence, the solution was excited at 490 nm, measuring emission at 515 nm with intervals of 0.1 second using a slit width of 2.5 nm for both monochromators. The vesicles were diluted in the respective buffers to a concentration of ~ 0.005 g/l or 5 µM. A 10 mm quartz cuvette with magnetic stirring was used and the vesicle solution was allowed to equilibrate for a minute before starting to record fluorescence. During the recording, protein was injected after 1 minute (defined as time t = 0) and the fluorescence was followed until it reached a plateau. Spectra were normalized with regards to maximum fluorescence, i.e. the fluorescence level achieved when 1% of Triton X-100 is added, using equation (4):
where F is the fluorescence intensity achieved by the peptides and F 0 and F t are fluorescence intensities without the peptides and with Triton X-100, respectively.
RESULTS
Antimicrobial activity -Minimal inhibitory concentration (MIC) was tested for 183 bacterial strains, the majority being gram-positive human pathogens of species Staphylococcus and Streptococcus. The more susceptible species were Streptococcus: S. pneumonia, S. pyogenes and S. agalactiae, they showed MIC values of 0.06 -1 µg/ml. A larger variation was seen among other species: MIC for Staphylococcus ssp were found to be in the range of 0.5 -128 µg/ml and for Enterococci 0.25 -128 µg/ml. As an example, the MIC for the susceptibility reference strains of important human grampositive pathogen bacteria were: Staphylococcus aureus (ATCC29213): 16µg/ml; Staphylococcus epidermidis (ATCC12228): 16µg/ml; Enterococcus faecium (ATCC49624): 16µg/ml; Enterococcus facalis (ATCC29212): 2µg/ml; Streptococcus pneumonia (ATCC49619): 0.25µg/ml No activity was seen among the gram-Negative bacteria tested here (MIC >32µg/ml). In vivo efficacy -When 10 mg/kg eurocin was administered, the concentration of viable Streptococcus pneumoniae in the peritoneum of mice dropped by approximately three orders of magnitude after 2 hours (Fig. 2B) . This was comparable to the effect of vancomycin when administered at 70 mg/kg. This reduction is paralleled by a similar reduction in the blood (data not shown). In the untreated controls, the concentration of viable Pneumococci in the peritoneum increased >10-fold during 5 h (data not shown). Eurocin is effective at low dosage concentrations against an intra-peritoneal infection with Streptococcus pneumoniae D39. Four hours after administration, the bacterial counts from both blood and peritoneal fluid showed an effect at concentrations of approximately 0.5 mg/kg. The Effective dose 50 (ED 50 ) was 2 mg/kg (Fig. 2C) . At the same time, eurocin was found noncytotoxic up to a concentration of 1024 g/ml (haemolytic effect of 0.5-4%, data not shown). Mammalian in vitro toxicity was examined using both L929 mouse fibroblasts and freshly prepared human erythrocytes. Both methods showed low cytotoxicity of eurocin even at the highest concentrations tested (1 mg/ml, data not shown). Table  S1 contains the classification of NOEs, the number of angle constraints used and criteria for quality assessment of the structure (CYANA target function, root mean square deviation (RMSD) and number of violations). Eurocin consists of a moderately flexible N-terminus, followed by an -helix ( 1 , residues A8-L18). After a turn, a beta strand ( 1 , residues T23-C27), followed by a flexible loop (residues A28-T37), leads to another -strand ( 2 , residue C38-S41) forming an antiparallel -sheet. The structure is illustrated in figure 3 . The structure of eurocin is thus highly homologous to other fungal and invertebrate defensin structures published. The three-dimensional structure of eurocin has been deposited to the Protein Data Bank, accession code 2LT8. Of the three proline residues, the peptide bond from C4 to P5 could be assigned a "cis" conformation based on the chemical shifts of C The relative orientation of the -sheet on one side and the N-terminal residues plus the -helix on the other side with respect to each other is defined by a number of long-range NOEs. Thermal stability - Figure 4 shows the pHstability profile of eurocin. Eurocin has the lowest denaturation temperature t m of 56.5±1.1 °C at pH 7. In the acidic range, t m increases steadily under more acidic conditions with the highest t m of 71.7±0.9 °C at pH 2. With increasingly alkaline pH values, t m increases, reaching a maximum t m of 70±2 °C between pH 10 and 11. At pH 12, t m is dropping again. Addition of 1 mM DTT causes the melting temperature at pH 4.5 to drop by 3.3 °C, in the presence of 20 mM of DTT, t m drops by 8 °C (data not shown). However, the protein unfolds in a cooperative fashion, indicating that intact disulfide bonds are not essential for the protein's ability to fold into a stable structure.
Interaction with lipids and detergents -
The CD spectrum of eurocin does not change upon interaction with either DPC or DHPC (data not shown). However, NMR data reveal a specific interaction between DPC and eurocin above the critical micelle concentration (cmc) of DPC. Figure 5A shows  abs as calculated by Eq. 2 plotted vs. the sequence of eurocin. The amino acids in the flexible loop between  1 and  2 as well as some adjacent amino acids in the Nterminus are affected by the presence of DPC, whereas there are only very small changes in chemical shift throughout the remaining part of the protein. The changes occur only at concentrations of DPC above its cmc (1.1mM (44)), not below. Based on the data and our structure, the SAMPLEX program (45) suggests residues 6 and 31-35 as core interaction site, which matches the most perturbed residues except for W31, where no data could be obtained. However, fluorescence data clearly indicate that W31 changes from a hydrophilic to a hydrophobic environment upon DPC binding ( Figure 5B ). DPC titration data can be fitted to a Langmuir isotherm yielding an affinity constant of 5268±1388, which corresponds to a G 0 of -21.2±0.8 kJ mol -1 , and N=11.1±1.1 ( Figure  5C ). Based on the clear evidence for interactions between eurocin and DPC, we investigated whether DPC affected the thermal stability of eurocin. Fig. 4 shows the t m values for eurocin in the presence of 0 and 32 mM DPC. Interestingly, binding to DPC micelles strongly increased the thermal stability in the acidic pH range, while thermal stability in the alkaline pH range is not significantly affected. The stability minimum shifts by approx. 1 pH unit towards the alkaline region.
Fluorescence measurements of peptide induced vesicle disruption -To observe whether the interaction between eurocin and lipid vesicles can lead to pore formation or membrane disruption, we prepared zwitterionic (100% DOPC) calcein-loaded lipid vesicles, and followed the calcein release as a function of eurocin concentration. Typical calcein-release data after the addition of eurocin to lipid vesicles can be seen in Fig. 6 . In all cases, the final amount of calcein released is well below 100% (as defined by the amount of calcein released by addition of Triton X-100), suggesting that the calcein leakage is neither due to pore formation nor total vesicle disruption. In support of this statement, we could not observe any peptide induced disruption of the vesicle membrane integrity by scanning laser confocal microscopy (data not shown).
Effect of eurocin on whole cells -
The reported binding of eurocin to lipid II suggests a mode of action of eurocin through interference with peptidoglycan biosynthesis. In order to investigate this in further detail, we first determined the cytoplasmic levels of UDPmuramic acid-pentapeptide (Fig. 7) . Antibiotics, such as vancomycin, that interfere with the late stages of peptidoglycan synthesis trigger an accumulation of this ultimate soluble peptidoglycan precursor in the cytoplasm. Treatment of S. simulans 22 with eurocin (10xMIC) led to significant accumulation of the soluble cell wall precursor UDP-MurNAcpentapeptide, similar to the extent of accumulation seen with vancomycin-treated controls (Fig. 7) . HPLC analysis and subsequent mass spectrometry confirmed the identity of UDP-MurNAc-pentapeptide (m/z 1148.3). The continuous biosynthesis of UDP-MurNAcpentapeptide and subsequent accumulation in the cytoplasm of treated cells further suggests that eurocin does not impair or depolarize the cytoplasmic membrane, since the precursor was retained in the cytoplasm and did not leak from treated cells. Membrane damage or pore formation should further result in a release of potassium from whole cells, however release of potassium was not observed after addition of eurocin at 1, 3, and 10 × MIC (corresponding to 0.069, 0.21, and 0.69 µM, respectively), compared to the pore forming lantibiotic nisin (data not shown), which rules out pore formation as mechanism of action.
Impact of eurocin on in vitro cell wall biosynthesis -Cell wall peptidoglycan is synthesized (46) starting from UDP-activated Nacetyl-muramic acid-pentapeptide, which is linked to a membrane carrier, bactoprenolphosphate (C 55 P) by the glycosyltransferase MraY, yielding lipid I. Lipid I is further glycosylated by MurG-catalyzed addition of an N-acetyl-glucosamine moiety to form the cell wall building block lipid II which is translocated across the cytoplasmic membrane to get assembled into the growing peptidoglycan network, this step being catalysed by enzymes collectively designated as PBPs. In staphylococci, lipid II is further modified by FemXAB-catalyzed addition of a pentaglycine chain to the pentapeptide (43) , where after the product is translocated to the outside of the cell to form the peptidoglycan layer, releasing the C 55 P molecule again.
Membrane preparations of Micrococcus luteus catalyse the membrane-associated synthesis (MraY and MurG) of lipid II in vitro, in the presence of defined amounts of the soluble precursors UDP-MurNAc-pentapeptide and UDP-GlcNAc and of the bactoprenol carrier C 55 -P. Addition of increasing concentrations of eurocin to this test system resulted in an inhibition of the overall lipid II synthesis, as observed by TLC (Fig. 8) . In the positive control, where no inhibitor was present, the complete conversion of C 55 -P to lipid II was achieved (Fig. 8A, lane 1) . Quantitative analysis, using radiolabeled precursors showed that increasing concentrations of eurocin led to enhanced inhibition of the lipid II synthesis and an almost complete inhibition was achieved at equimolar concentrations of antibiotic to lipid carrier (Fig. 9A) . To further characterize the inhibitory nature of eurocin we tested its impact on the individual PBP2-catalyzed transglycosylation/transpeptidation reaction, which occurs at the extracytoplasmic site of the membrane and therefore is the likely target reaction of eurocin. Reconstitution of the PBP2 catalyzed lipid II polymerisation in vitro and subsequent TLC analysis and quantification of residual 14 C-lipid II, revealed that eurocin completely inhibited lipid II conversion at equimolar ratio of eurocin to lipid II, suggesting a 1:1 complex of peptide:lipid II (rather than inhibition of the enzyme). Binding stoichiometry of eurocin and lipid II was further validated by incubating purified 14 C-lipid II together with eurocin in various molar ratios. Subsequent TLC was used to analyse the migration behaviour (Fig. 9B) . Free lipid II migrated to a defined position on the chromatogram (lane 1), while free eurocin was not detectable. However, in complex with eurocin, lipid II remained close to the starting point (lanes 3-5), as observed with the positive control nisin (lane 2). As has been observed in the cell-free assays, only at equimolar ratio, no free lipid II was detectable, substantiating the formation of a 1:1 stoichiometric eurocin:lipid II complex.
DISCUSSION
Structure -The 3D-structure of eurocin can be classified as a CS fold. This class of proteins comprises several defensins from insects, invertebrates and fungi, like insect defensin A (13), Lucifensin (19) , mediterranean mussel defensin MGD-1 (18), oyster defensin from Crassotrea gigas (47) , micasin from the dermatophytic fungus Microsporum canis (48) and plectasin from the saprophytic fungus Pseudoplectania nigrella (20) . The members of the CS family show the common feature of being toxic to cells, however, they achieve this toxicity through different functions. Scorpion toxins have been found to inhibit potassium channels (49, 50) . Micasin was suggested to act intracellularly through interference with protein folding (48) . Plant -thionins are a group of peptides with a variety of antibacterial and antifungal activities (51) . In some cases, the mode of action is known, e.g. Cp-thionin inhibiting proteases (52) and -hordothionin inhibiting -amylase (53). Apart from plectasin and micasin, eurocin is the only fungal defensin with a known 3D-structure. Mammalian defensins belong to a different structural family (54, 55) , e.g. human -defensin-2, which consists of a helical segment and a threestranded -sheet (54). Like MGD-1, eurocin also exhibits a cis-proline at position 4. Since cis-prolines rarely succeed cysteine residues (56), there must be a special reason for this peculiar geometry. Both the cysteine and the proline residue are conserved, the disulphide-forming cysteine even to 100% (see Fig. 1 ) in the sequences described so far, further corroborating the essential role of the proline residue at this position in the sequence. The only exception is plectasin, where two extra amino acids are inserted between the cysteine and the proline, and where proline is in transconformation. The remaining two proline residues of eurocin, P30 and P36, which are not conserved in homologous proteins, show a transconformation. Given their location on both termini of the flexible loop connecting the two -strands, they probably act as secondary structure breakers. A striking feature of the structure is the absence of a hydrophobic core. Fig. 3 shows the location of the hydrophobic residues of eurocin. They are scattered around the surface with a concentration of 3 hydrophobic residues in a row in the flexible loop, that was seen to interact with DPC micelles. Fig. 3 shows the location of charged residues, and demonstrates, that salt bridges are not involved in keeping the tertiary structure of the protein intact. Neither could any H-bonds be found between residues in the helix and residues in the -sheet. The fold seems to be kept intact solely by the three disulfide bridges. This is corroborated by the marked decrease of the denaturation temperature, t m , in the presence of DTT.
Interaction with micelles and vesicles -
The majority of antimicrobial peptides have been found to interact with membrane lipids or lipid mimics like detergents. Eurocin is no exception, in that it was found to interact with DPC micelles in a well-defined way. The interaction site was found around the three hydrophobic residues W31, Y32 and L33 in the flexible loop, and to a minor extent in the neighbouring Nterminal loop (G6). The resonances of W31, Y32 and L33 were considerably weaker than other resonances in the absence of DPC, possibly as a consequence of increased molecular mobility. After binding to DPC micelles, the resonances became approximately as strong as other residues. This hints at a reduced mobility of the loop after interaction with the micelle. NMR signals of the DPC bound form of eurocin were generally broader and weaker than the signals of the free form, as can be expected due to slower molecular tumbling. No high-resolution structure of the DPC bound form was calculated. However, the limited changes occurring in the NOESY spectra of the bound form clearly demonstrate that no overall change in structure took place as a consequence of interaction with the micelles. This no doubt reflects rigidity in the structure imparted by the three disulfide bonds.
The data suggest a binding of eurocin to the surface of the micelle. However, the peptide does not seem to penetrate the micelle deeply. This makes pure membrane disruption a very unlikely mechanism of action for eurocin. This was further substantiated by the data obtained on real phospholipids by vesicle disruption experiments: although the eurocin concentrations tested were above a protein to lipid ratio of 5 and between 30 and 240 x MIC, we could not observe complete release of vesicle contents in contrast to the high efficiency reported for antimicrobial peptides such as Ac-RRWWRF-NH2 (57), Hnp-2 (58), Gramicidin A, Gramicidin S, amphotricin (59) and melittin (60) that are proposed to work by either barrelstave, torroidal pore or carpet mechanism. The synthetic antimicrobial peptide Novispirin (61, 62) effects full release of calcein from 5 µM lipid at 0.2 µM peptide, which is around two orders of magnitude more efficient than that of eurocin (63) . Thus eurocin is clearly a very inefficient membrane permeabiliser, and membrane permeabilization is not the primary mode of its action. It is, however, worth noting that eurocin binds to lipid aggregates even if there is no lipid II, its natural ligand, present.
It is interesting to compare the DPC binding sites on the surfaces of eurocin and plectasin:
Figs. 3E and 3F show the two peptides with their respective binding sites. DPC binding occurs at the same end of the peptide molecule, where there are two loops, one connecting the Nterminus with helix 1 and the other connecting the two -strands. In plectasin, both loops are approximately equally long, the N-terminal loop being slightly longer. In eurocin, the N-terminal loop is much shorter than the loop connecting the two -strands. Looking at the sequence alignment ( Fig. 1) in the loop regions, it can be seen that the extended N-terminal loop is a unique feature of plectasin (residues N5-W8 inserted), while the loop connecting the two -strands seems to be extended by three amino acids (G34-P36) in eurocin compared to other invertebrate defensins. The free energy of binding of eurocin to DPC micelles was found to be -21.2 ± 0.8 kJ/mol. This is weaker than the -27 ± 1 kJ/mol found for plectasin. This probably reflects the smaller buried solvent accessible surface area of 1040 Å 2 for eurocin (calculated as the solvent accessible surface area of residues G6, W31, Y32, L33, G34 and H35) compared to 1145 Å 2 for plectasin (residues G6, W8, D9, A31, K32, G33, G34, F35, V36, and C37).
Antimicrobial effect -like plectasin, eurocin has a much stronger effect on Gram-positive bacteria than on Gram-negative bacteria. This is contrasted by micasin, which shows good antimicrobial activity against the gram-negative P. aeruginosa and A. tumefaciens. This difference is a further indication that eurocin and plectasin on the one hand and micasin on the other hand have different mechanisms of action. Eurocin is shown here to efficiently combat a range of Gram-positive infections both in vitro and in vivo.
Mechanism of action -The experimental results obtained on the impact of eurocin on cell wall synthesis allows a clear picture of eurocin's mode of action. Using a combination of in vivo and in vitro test systems we found that the defensin eurocin selectively inhibits peptidoglycan biosynthesis through complex formation with the cell wall precursor lipid II. Sequestration of the central cell wall precursor lipid II prevents the incorporation in the growing peptidoglycan network and the formation of a vital cell wall, as revealed by inhibition of the PBP-catalyzed polymerisation of lipid II in vitro. In this system eurocin was found to almost completely inhibit the lipid II consuming reaction at equimolar ratio (peptide:lipid), strongly suggesting complex formation rather than inhibition of the enzyme PBP2. The TLC experiment further confirmed the formation of a specific eurocin:lipid II complex observed in the cell-free assays. This is essentially the same mechanism, like that of the fungal defensin plectasin (25) . Our observation that eurocin binds to and is stabilized by phospholipid-like micelles and interacts with phospholipid vesicles, demonstrates eurocin's affinity for phospholipids. This affinity helps prepositioning the peptide at the cell surface where its ligand lipid II occurs.
In line with the accumulation of the ultimate soluble cell wall precursor UDP-MurNAcpentapeptide in the cytoplasm upon treatment with eurocin, we could not observe eurocininduced potassium release from whole cells, indicating that eurocin does not impair membrane integrity or induces the formation of pores in the cytoplasmic membrane.
CONCLUSION
Eurocin is a fungal defensin with a CS fold as seen for other defensins. Eurocin binds to lipid aggregates, but its primary mode of action is not the formation of pores in cell membranes. In vivo and in vitro analysis of eurocin's mechanism of action revealed that the peptide inhibits peptidoglycan biosynthesis of grampositive bacteria without comprising membrane integrity. Antimicrobial assays carried out both in vivo and in vitro showed that eurocin is a fast and effective antibiotic against Streptococci even at low concentrations, while it does not show good activity against gram-negative pathogens.
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